Categories: October 14, 2026 We hope you appreciated this article! Before you move on, please consider supporting The Appalachian's award-winning journalism. The bulk of our operational expenses — including printing, website hosting, training, and entering our work into competitions — is dependent upon advertising revenue and donations.
Devin McLaughlin
New Jersey, Pleasantville
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Devin McLaughlin
Buggy Goes To Class
Categories: September 15, 2026 We hope you appreciated this article! Before you move on, please consider supporting The Appalachian's award-winning journalism. The bulk of our operational expenses — including printing, website hosting, training, and entering our work into competitions — is dependent upon advertising revenue and donations.
Selinexor maintenance extends PFS in endometrial cancer subgroup with high unmet need
Source/Disclosures Source: Slomovitz BM, et al. Abstract 427956. Presented at: ASCO Plenary Series: July 2023 Session; July 25, 2023. Disclosures: Karyopharm Therapeutics provided research funding for this study. Slomovitz reports consultant/advisory roles with Agenus, AstraZeneca, Eisai, Eli Lilly & Co., EQRx; Genentech, GOG Foundation, GSK, Incyte, Merck, Myriad Genetics, Nuvation Bio, Onconova Therapeutics and Regeneron.
Nivolumab regimen ‘a huge advance’ in treatment of classical Hodgkin lymphoma
Source/Disclosures Source: Herrera AF, et al. Abstract LBA4. Presented at: ASCO Annual Meeting 2023; June 2-6, 2023: Chicago. Disclosures: NCI and NIH funded this study.
Neoadjuvant FOLFIRINOX fails to extend survival in resectable pancreatic cancer
Jashodeep Datta, MD Pancreatic ductal adenocarcinoma (PDAC) is a devastating malignancy, owing in part to the fact that most patients present with advanced disease, with only 20% of patients eligible for surgical resection. The dismal oncologic outcomes with surgery alone, and the near universal distant failure, in patients with operable PDAC have mandated a multimodality approach for this disease.
Gilead terminates phase 3 trial of magrolimab regimen for myelodysplastic syndrome
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. A phase 3 trial of magrolimab plus azacitidine for higher-risk myelodysplastic syndrome has been terminated because of futility, according to a press release.
Pembrolizumab plus chemoradiotherapy extends PFS in advanced cervical cancer
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. The addition of pembrolizumab to concurrent chemoradiotherapy conferred a statistically significant and clinically meaningful increase in PFS among women with newly diagnosed high-risk locally advanced cervical cancer, topline data showed.
Osimertinib after surgery reduces risk for death by 51% in resected
Source/Disclosures Source: Herbst RS, et al. Abstract LBA3. Presented at: ASCO Annual Meeting 2023; June 2-6, 2023: Chicago. Disclosures: AstraZeneca funded this study.
FDA approves Talzenna regimen for certain men with metastatic prostate cancer
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. FDA approved talazoparib plus enzalutamide for treatment of homologous recombination repair gene-mutated metastatic castration-resistant prostate cancer.
Pembrolizumab regimen fails to hit EFS target in gastric, gastroesophageal junction cancer
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. The addition of pembrolizumab to perioperative chemotherapy failed to significantly extend EFS among patients with locally advanced resectable gastric and gastroesophageal junction adenocarcinoma, according to the agent’s manufacturer.
New models enable deeper research into acute myeloid leukemia
Source/Disclosures Disclosures: Papapetrou reports personal fees from Janssen and Regeneron outside the submitted work. Source/Disclosures Disclosures: Papapetrou reports personal fees from Janssen and Regeneron outside the submitted work. We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
ASCO chief medical officer appeals to Congress for action on cancer-drug shortages
Source/Disclosures Source: ASCO in Action. ASCO chief medical officer testifies to Congress on mitigating and preventing cancer drug shortages. Available at: https://old-prod.asco.org/news-initiatives/policy-news-analysis/asco-chief-medical-officer-testifies-congress-mitigating-and. Published June 13, 2023. Accessed June 14, 2023. We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
Mirvetuximab soravtansine data ‘practice changing’ for subset of women with ovarian cancer
Source/Disclosures Source: Moore K, et al. Abstract LBA5507. Presented at: ASCO Annual Meeting; June 2-6, 2023; Chicago. Disclosures: Immunogen funded this research.
Novel AhR inhibitor shows tolerability, activity in advanced solid tumors
Source/Disclosures Source: Dumbrava EE, et al. Abstract 2502. Presented at: ASCO Annual Meeting; June 2-6, 2023; Chicago. Disclosures: Bayer AG provided research funding for this study. Dumbrava reports an advisory/consulting role with Bolt Biotherapeutics and research funding from Aileron Therapeutics, Amgen, Aprea Therapeutics, Astex Pharmaceuticals, Bayer, Bellicum Pharmaceuticals and several other pharmaceutical companies.
Sintilimab reduces recurrence risk in locoregionally advanced nasopharyngeal carcinoma
Source/Disclosures Source: Ma J, et al. Abstract LBA6002. Presented at: ASCO Annual Meeting; June 2-6, 2023; Chicago. Disclosures: Ma reports research funding from Bristol Myers Squibb and Varian Medical Systems. Please see the abstract for all other researchers’ relevant financial disclosures. We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
Benefits of ivosidenib regimen for
Source/Disclosures Source: De Botton S, et al. Abstract 7012. Presented at: ASCO Annual Meeting; June 2-6, 2023; Chicago. Disclosures: De Botton reports relationships with AbbVie, Astellas Amgen BioPharama, Auron Therapeutics, Bristol Myers Squibb, Forma Therapeutics, GSK, Jazz Pharmaceuticals, Loxo Oncology, Remix Therapeutics, Servier and Syndax. Please see the abstract for all other researchers’ relevant financial disclosures. Source/Disclosures Source: De Botton S, et al. Abstract 7012.
Trastuzumab deruxtecan shows ‘broad activity’ in HER2-expressing solid tumors
Source/Disclosures Source: Meric-Bernstam F, et al. Abstract LBA3000. Presented at: ASCO Annual Meeting; June 2-6, 2023; Chicago. Disclosures: AstraZeneca and Daiichi Sankyo supported this study.
Strategy may enable some patients with HER2-positive breast cancer to avoid chemotherapy
Source/Disclosures Source: Cortés J, et al. Abstract LBA506. Presented at: ASCO Annual Meeting; June 2-6, 2023; Chicago. Disclosures: Roche sponsored this research. Cortes reports stock ownership in Leuko, MedSIR and Nektar Therapeutics, as well as relationships with AstraZeneca, Celgene, Daiichi Sankyo, Eisai, Eli Lilly, Merck Sharp & Dohme, Novartis, Pfizer, Roche and several other companies. Please see the abstract for all other researchers’ relevant financial disclosures.
Toripalimab regimen delays progression of PD-L1-positive triple-negative breast cancer
Source/Disclosures Source: Jiang ZF, et al. Abstract LBA1013. Presented at: ASCO Annual Meeting; June 2-6, 2023; Chicago. Disclosures: Shanghai Junshi Biosciences Co., Ltd supported the study. Liu reports advisory/consultant roles with AstraZeneca and Novartis; speakers bureau roles with AstraZeneca, Eisai, Novartis, Pfizer and Roche; and research funding from Eisai. Please see the abstract for all other researchers’ relevant financial disclosures. Source/Disclosures Source: Jiang ZF, et al.
Talazoparib extends PFS in maintenance regimen for small cell lung cancer subgroup
Source/Disclosures Source: Abdel Karim NF, et al. Abstract 8504. Presented at: ASCO Annual Meeting; June 2-6, 2022; Chicago. Disclosures: Genentech funded this study. Abdel Karim reports speakers bureau/advisory board roles with or research funding from Amgen, AstraZeneca, Bristol Myers Squibb, Exelixis, G1 Therapeutics, Genentech, Jazz Pharmaceuticals, Merck, Pfizer and Regeneron. Please see the abstract for all researchers’ relevant financial disclosures.
Long-duration trastuzumab remains standard of care in HER2-positive breast cancer
Source/Disclosures Source: Conte PF, et al. Abstract LBA637. Presented at: ASCO Annual Meeting; June 2-6, 2023; Chicago. Disclosures: Agenzia Italiana del Farmaco sponsored the study. Conte reports no relevant financial disclosures. Please see the abstract for all other researchers’ relevant financial disclosures. Source/Disclosures Source: Conte PF, et al. Abstract LBA637. Presented at: ASCO Annual Meeting; June 2-6, 2023; Chicago. Disclosures: Agenzia Italiana del Farmaco sponsored the study.
Nivolumab regimen ‘a huge advance’ in treatment of classical Hodgkin lymphoma
Source/Disclosures Source: Herrera AF, et al. Abstract LBA4. Presented at: ASCO Annual Meeting 2023; June 2-6, 2023: Chicago. Disclosures: NCI and NIH funded this study.
Osimertinib after surgery reduces risk for death by 51% in resected
Source/Disclosures Source: Herbst RS, et al. Abstract LBA3. Presented at: ASCO Annual Meeting 2023; June 2-6, 2023: Chicago. Disclosures: AstraZeneca funded this study.
Vorasidenib first ‘game changer’ in 20 years for patients with
Source/Disclosures Source: Mellinghoff IK, et al. Abstract LBA1. Presented at: ASCO Annual Meeting 2023; June 2-6, 2023: Chicago. Disclosures: Mellinghoff reports honoraria from Roche; a consulting/advisory role with Agios, Black Diamond Therapeutics, Debiopharm Group, Puma Biotechnology and Voyager Therapeutics; research funding from Amgen, General Electric and Lilly O; and travel, accommodations and expenses from Agios, AstraZeneca, Puma Biotechnology, Roche and Voyager Therapeutics.
Neoadjuvant chemotherapy regimen shows durable survival benefit in rectal cancer
Source/Disclosures Source: Conroy T, et al. Abstract LBA3504. Presented at: ASCO Annual Meeting; June 2-6, 2023; Chicago. Disclosures: Conroy reports no relevant financial disclosures. Please see the abstract for all other researchers’ relevant financial disclosures. Source/Disclosures Source: Conroy T, et al. Abstract LBA3504. Presented at: ASCO Annual Meeting; June 2-6, 2023; Chicago. Disclosures: Conroy reports no relevant financial disclosures.
Patients with locally advanced rectal cancer can safely be spared pelvic radiation
Source/Disclosures Disclosures: Schrag reports stock and other ownership interests in Merck, a consulting/advisory role with JAMA, institutional research funding from AACR and Grail, patents, royalties or other intellectual property with PRISSMM model, and other relationships with JAMA. Please see the abstract for all other researchers’ relevant financial disclosures.
Data confirm benefit of dostarlimab regimen for women with advanced endometrial cancer
Source/Disclosures Source: Powell MA, et al. Abstract 5503. Presented at: ASCO Annual Meeting; June 2-6, 2023; Chicago. Disclosures: GSK provided funding for this study. Powell reports consultant/advisory roles with AstraZeneca, Clovis Oncology, Eisai, GSK/Tesaro, GOG Partners, Roche/Genentech, Seagen and Tesaro, and institutional research funding from GSK/Tesaro. Please see the abstract for all other researchers’ relevant financial disclosures. We were unable to process your request.
Nearly 1 in 4 academic oncologists report burnout
Source/Disclosures Source: Odei B, et al. Abstract 11000. Presented at: ASCO Annual Meeting; June 2-6, 2023; Chicago. Disclosures: Chino reports no relevant financial disclosures. Please see the abstract for all other researchers’ relevant financial disclosures. Source/Disclosures Source: Odei B, et al. Abstract 11000. Presented at: ASCO Annual Meeting; June 2-6, 2023; Chicago. Disclosures: Chino reports no relevant financial disclosures.
One-third of women oncologists experience infertility
Source/Disclosures Source: MacDuffie E, et al. Abstract 11001. Presented at: ASCO Annual Meeting; June 2-6, 2023; Chicago. Disclosures: The researchers report no relevant financial disclosures. We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Key takeaways: Twenty percent reported spending $30,000 or more on ART.
Olaparib-durvalumab regimen prolongs PFS for certain women with advanced ovarian cancer
Source/Disclosures Source: Harter P, et al. Abstract LBA5506. Presented at: ASCO Annual Meeting 2023; June 2-6, 2023: Chicago. Disclosures: Aghajanian reports consulting/advisory roles with and/or research funding from AbbVie, AstraZeneca, Clovis Oncology, Eisai, Genentech/Roche, Merck, and Repare Therapeutics.
Neoadjuvant FOLFIRINOX fails to extend survival in resectable pancreatic cancer
Source/Disclosures Source: Labori KJ, et al. Abstract LBA4005. Presented at: ASCO Annual Meeting; June 2-6, 2023; Chicago. Disclosures: Norwegian Cancer Society South-Eastern Norway Regional Health Authority, the Sjøberg Foundation and a Helsinki University Hospital research grant funded this study. One author reports a consultant/advisory role with AstraZeneca and another reports stock/other ownership interests in AnOn Medical AB. Source/Disclosures Source: Labori KJ, et al. Abstract LBA4005.
AYAs with rare leukemia face disparities in access to specialized cancer centers
Source/Disclosures Source: Muffly L, et al. Abstract 7008. Presented at: ASCO Annual Meeting; June 2-6, 2023; Chicago. Disclosures: The Leukemia and Lymphoma Society provided funding for this study.
Minimally invasive surgery ‘safe, valid’ alternative to open approach for pancreatic cancer
Source/Disclosures Source: Abu Hilal M, et al. Abstract 4163. Scheduled for presentation at: ASCO Annual Meeting; June 2-6, 2023; Chicago. Disclosures: Ethicon and Medtronic funded this study. Abu Hilal reports research funding from Ethicon and Medtronic. Please see the abstract for all other researchers’ relevant financial disclosures. Source/Disclosures Source: Abu Hilal M, et al. Abstract 4163. Scheduled for presentation at: ASCO Annual Meeting; June 2-6, 2023; Chicago.
GI cancer death rates, survival disparities decrease after Medicaid expansion
Source/Disclosures Source: Manisundaram N, et al. Abstract 6546. Scheduled for presentation at: ASCO Annual Meeting; June 2-6, 2023; Chicago. Disclosures: NIH funded this study. One researcher reports a consultant/advisory role with Medicaroid. Gralow reports no relevant financial disclosures. Source/Disclosures Source: Manisundaram N, et al. Abstract 6546. Scheduled for presentation at: ASCO Annual Meeting; June 2-6, 2023; Chicago. Disclosures: NIH funded this study.
Perioperative durvalumab-based therapy reduces risk for adverse lung cancer outcomes
Source/Disclosures Source: Heymach JV, et al. Abstract CT005. Presented at: American Association for Cancer Research Annual Meeting; April 14-19, 2023; Orlando. Disclosures: AstraZeneca sponsored this study.
Adding enzalutamide to ADT cuts risk for metastasis by 58% in prostate cancer subgroup
Source/Disclosures Disclosures: Astellas and Pfizer funded this study. Shore reports grant support and consulting fees from AbbVie, Amgen, Astellas Pharma, AstraZeneca, Bayer, Clovis Oncology, Dendreon Pharmaceuticals LLC, Ferring Pharmaceuticals, GenesisCare, Janssen Oncology, Merck, Myovant Sciences, Pfizer, Sanofi-Genzyme and Tolmar Pharmaceuticals. Please see the abstract for all other researchers’ relevant financial disclosures. We were unable to process your request. Please try again later.
Perioperative toripalimab regimen extends EFS in resectable stage III NSCLC Original
Source/Disclosures Source: Lu S, et al. Abstract 425126. Presented at: ASCO Plenary Series: April 2023 Session; April 20, 2023. Disclosures: Junshi Biosceinces sponsored this study.
Biden to nominate National Cancer Institute director for top NIH post
April 20, 2023 1 min read Biden to nominate National Cancer Institute director for top NIH post ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Subscribe We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Back to Healio President Joe Biden plans to nominate NCI Director Monica M.
Deep learning model predicts risk for distant recurrence of endometrial cancer
Maurie Markman, MD It is difficult to read a medical journal today without seeing some discussion of artificial intelligence, whether praising the potential clinical utility of a particular research effort or raising concerns for possible bias in existing algorithms or premature introduction into medical practice.
Pembrolizumab plus chemotherapy prolongs survival in advanced biliary tract cancer
Source/Disclosures Source: Kelley RK, et al. Abstract CT008. Presented at: American Association for Cancer Research Annual Meeting; April 14-19, 2023; Orlando. Disclosures: Merck Sharp & Dohme funded this study.
Perioperative durvalumab-based therapy reduces risk for adverse lung cancer outcomes
Source/Disclosures Source: Heymach JV, et al. Abstract CT005. Presented at: American Association for Cancer Research Annual Meeting; April 14-19, 2023; Orlando. Disclosures: AstraZeneca sponsored this study.
Ibrutinib indications for mantle cell, marginal zone lymphoma to be voluntarily withdrawn
April 07, 2023 1 min read Ibrutinib indications for mantle cell, marginal zone lymphoma to be voluntarily withdrawn ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Subscribe We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
Research underscores value of healthy lifestyle choices among childhood cancer survivors
Source/Disclosures Disclosures: The NCI and American Lebanese Syrian Associated Charities funded this study. Dixon, Marcil and Tonorezos report no relevant financial disclosures. Source/Disclosures Disclosures: The NCI and American Lebanese Syrian Associated Charities funded this study. Dixon, Marcil and Tonorezos report no relevant financial disclosures. We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
Study of pembrolizumab regimen in endometrial cancer yields ‘encouraging new finding’
Source/Disclosures Source: Eskander RN, et al. NRG GYO18/KEYNOTE-868: A phase III randomized, placebo-controlled study of pembrolizumab in addition to paclitaxel and carboplatin for measurable stage III or IVA, stage IVB or recurrent endometrial cancer (late-breaking abstract). Presented at: Society of Gynecologic Oncology Annual Meeting on Women’s Cancer; March 25-28, 2023; Tampa, Florida. Disclosures: Merck sponsored the trial.
Neoadjuvant olaparib feasible for women with germline-mutant ovarian cancer
Source/Disclosures Source: Westin SN, et al. NOW: Neoadjuvant olaparib window trial in newly diagnosed BRCA-mutant ovarian cancer (late-breaking abstract). Presented at: Society of Gynecologic Oncology Annual Meeting on Women’s Cancer; March 25-28, 2023; Tampa, Florida. Disclosures: AstraZeneca sponsored the trial.
Zolbetuximab regimen extends survival in gastric, gastroesophageal junction cancer subset
Source/Disclosures Source: Xu R, et al. Abstract 405736. Presented at: ASCO Plenary Series: March 2023 Session; March 22, 2023. Disclosures: Astellas Pharma sponsored the study. Shah reports study funding to the participating institution from Astellas Pharma, Bristol Myers Squibb, Merck and Oncolys BioPharma, as well as a leadership/fiduciary role on the ASCO Leadership Council. Please see the abstract for all other researchers’ relevant financial disclosures.
FDA advisory panel backs polatuzumab vedotin-piiq benefit-risk profile in first-line DLBCL
Source/Disclosures We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Key takeaways: The Oncologic Drugs Advisory Committee voted 11-2 that polatuzumab vedotin-piiq has a favorable benefit-risk profile for patients with previously untreated LBCL. The FDA is expected to make a final decision on a supplemental biologics license application for the indication by April 2.
FDA expands Verzenio approval for high-risk breast cancer
March 03, 2023 1 min read FDA expands Verzenio approval for high-risk breast cancer ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Subscribe We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
Cancer screenings in US continued to lag during year 2 of pandemic
Source/Disclosures Disclosures: One author reports employment with Syneos Health and another reports research funding from AstraZeneca. Source/Disclosures Disclosures: One author reports employment with Syneos Health and another reports research funding from AstraZeneca. We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
Iomab-B may increase transplant access, improve outcomes in relapsed/refractory AML
Source/Disclosures Source: Gyurkocza B, et al. Abstract LBA3. Presented at: Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, Feb. 15-19, 2023; Orlando. Disclosures: Giralt reports relationships with Actinium Pharmaceuticals, Amgen, Bristol Myers Squibb, Celgene, GSK, Janssen, Jazz Pharmaceuticals, Johnson & Johnson, Kite Pharma, Miltenyi Biotec, Novartis, Omeros, Pfizer, Sanofi, Spectrum Pharmaceuticals and Takeda.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Devin
Contact Devin, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack